Report claims Citadel invests $1.7M in XRP exchange-traded funds amid rising institutional interest
A media report claims that Citadel has invested approximately $1.7 million in XRP-focused exchange-traded products, underscoring continued institutional exploration of digital asset exposure. The report has not been independently verified, and key details — including the specific products and jurisdictions involved — remain unclear.
What’s been reported
According to the report, Citadel’s allocation targets funds that track XRP, the native token used on the XRP Ledger for cross-border value transfers. Neither Citadel nor Ripple has publicly confirmed the investment, and no corresponding regulatory filings were immediately available for review.
ETF or ETP? Understanding XRP investment products
While spot Bitcoin and Ether exchange-traded funds have launched in the United States, there are currently no U.S.-listed spot XRP ETFs. However, XRP-tracking exchange-traded products (ETPs) are listed in some jurisdictions outside the U.S., providing institutional and professional investors with regulated exchange exposure to the asset. The report did not specify whether the cited holdings are in U.S. ETFs (if any are approved in the future) or non-U.S. ETPs.
Why it matters
- Institutional participation: Even relatively small allocations by large financial firms can signal growing institutional willingness to engage with a broader set of crypto assets beyond Bitcoin and Ether.
- Market maturation: Interest in diversified crypto products suggests ongoing integration of digital assets into traditional market infrastructure.
- Ripple ecosystem context: XRP serves as the native asset of the XRP Ledger, which is used for fast, low-cost transfers. Greater institutional familiarity with XRP-linked products could influence liquidity and market depth over time.
Regulatory backdrop
Regulatory clarity remains a key factor for wider adoption of XRP-linked funds. U.S. approval pathways for non-Bitcoin, non-Ether crypto ETFs are uncertain, and product availability varies significantly by jurisdiction. Any confirmed institutional allocations to XRP-tracking funds should be evaluated in light of these regulatory differences.